The Healthcare Finance Double Asset Forum on the theme of new pattern of medical investment in Europe and the US was officially launched in Guangzhou on September 8th. Mr. Herve de Kergrohen, the initiator of BioData Forum and investor of American health reform, Mr. Xiao Weizhong, the deputy party secretary of Guangzhou Daily Press Group and vice president of Guangdong Media, and Mr. Lin Gang and Mr. Pan Jiang Xiang, the Chinese executive directors of SMI Swiss Medical International Investment Group all attended the forum and delivered speeches.

more...

In consideration of the new pattern of medical investment in Europe and the US, Health Care Finance Double Asset Forum will bring together many of the world’s top medical authorities from America and Europe, as well as international medical investment experts.

more...

Biodata International Medical Investment Forum & Symposium

The “Biodata International Medical Investment Forum & Symposium” held in HK on 17th April 2015, was organized by SMI SWISS International and co-organized by Wharton Business School and Cornell University.

The Forum & Symposium officially started from 9 am on 17th April.

more...

The financial BioData symposium showcases the life sciences in Geneva. An opportunity for many start-up to establish privileged contacts with investors from all backgrounds.

The Minister of Economy proposed this morning in St. Julien-en-Genevois, the touchstone of a biomanufacturing unit of antibodies immunology Centre--Pierre-Fabre .The biotech industry can be a chance for Haute-Savoie. Read also the interview with Christine Lagarde.

Hervé de Kergrohen, who is the organizer of the Biodata salon, he was satisfied with the biotechnology projet, during this two days, he has met well with the investors and the boss of the companies.He said that the level is high for all the participants this year, in the plan of the organization, the presentation have succeeded without dead time, and during the presentation, there was a few themes such as Alzheimer's disease or oncology disease. “many diseases are not sufficiently treatable, some innovations are just the evolutions and some are undoubtedly the revolutions”said the Hervé de Kergrohen. For the treatment of major diseases

more...

The event has undoubtedly found its stride at the dawn of its seventh edition. BioData, high mass Romande biotech companies, will take place on 22 and 23 January in Geneva, in the presence of multiple actors in the life sciences sector (see below).

The Geneva Minister Pierre-François Unger. "This is an important event in the field of life sciences, critical to our economy."
Image: LAURENT GUIRAUD

more...

FINANCE Le Temps Finance I Article The market downturn will push small biotech R&D into alliances. The end of the prospect of development of young companies by IPO will result in the pharmaceutical sector consolidation wave.
Willy Boder Wednesday, January 23, 2008 "The window wide open in 2006-2007 abruptly closed.

Maybe he will have to wait two years to see it open again r "Hervé de Kergrohen, President of BioData '; until the effects of the storm ends on the sector of biotech. One of first consequences is closing the "IPO window", the end of the ambitions to go public to value a young company and recover research costs tens of millions of francs accumulated during the start-up years. But without stock market and without financing from venture capital, increasingly hard to find in Europe, the logical solution for a company're running research budget will be flowing into the arms of a large company .

more...

Geneva (ats) More than 350 economic actors participated in the 3rd edition of BioData symposium on 20 and 21 January in Geneva. This success reflects the market's confidence in the growing sector of biotechnology, according to organizers.

Some 45 companies active in biotechnology attended the Geneva forum. Almost half of them are Swiss firms, including five publicly traded, said Wednesday the ats Christophe Lamps, an organizer of BioData 2004 symposium.

This conference is an opportunity for companies to take stock of the evolution of this sector of the economy and develop a vision for the coming year. The Swiss Association of biotechnology, which includes all firms active in this area, it participated for the first time, has pointed Lamps.

French-Swiss Foundation

BioData, international symposium that brings together every year in Geneva over fifty biopharma companies and medtech investors and partners, will be held on 23 and 24 January 2007 at the Ramada Park Hotel. This annual meeting allows biotechnology companies representatives to present to potential investors while creating links that may provide new opportunities for development.

The 2010 edition will host over seventy specialized investors and nearly 250 "one to one" are programmed between these entrepreneurs and financial experts. And enrollment is almost similar to that of 2008, when the last edition. "This is proof of the interest of the manifestation" adds Hervé de Kergrohen Chairman of Biodata.

more...

By the ATS 15.01.2008 at 16:18

"This is an important event in the field of life sciences, critical to our economy," said Tuesday before the press Pierre-François Unger, Geneva's Minister of Economy and Health. They also affects the timing of the first meeting of the year bringing together all the players in a booming sector. 50 companies to discover "BioData was built on this integrated mode" recalled Mr. Unger.

"This is an important event in the field of life sciences, critical to our economy," said Tuesday before the press Pierre-François Unger, Geneva's Minister of Economy and Health. They also affects the timing of the first meeting of the year bringing together all the players in a booming sector. 50 companies to discover "BioData was built on this integrated mode" recalled Mr. Unger. The event helps strengthen "the Lake Geneva region in life sciences," around a large area including several French-speaking cantons and Rhone Alps in neighboring France. A set that includes "some 2 million people, with numerous key jobs."

more...

When we will see a film at the Gaumont or buy a CD at Virgin, we do not doubt that somewhere in the floors of the Alliance building, or in the surrounding area to large companies like apartments are developing high-flying technologies , applied to the life science, that is to say we humans. So what Gaillard and Saint-Julien-en-Genevois are implanted in very big companies (Bayer Health Home and Pierre Fabre) in the technology park of Archamps a scientific hive activates finding drugs, treatments, or designs of equipment "France offers the best conditions in Switzerland for the establishment of new companies" serious diseases such as cancer and neurodegenerative diseases are the target start-ups based in the French Genevois, specifically the "southern Porte de Geneve". Some of these companies are bi-locals, with headquarters in Switzerland, or simply choose to settle in France, because it would become Interestingly government grants and tax credits, as well as the status of young innovative company, had an effect "France now offers the best conditions in Switzerland for the establishment of new businesses," said Herve Kergrohen, Biodata show organiser. Haute-Savoie intends to pull out of the game for Roland Pascal, chairman of the board of the Archamps Technopole, "we must affirm our vocation for biotechnology. The bow is a biotechnology location main homes in Europe and Haute savoie must take his share in biotechnology.

more...

It is a discrete business in the Savoyard Genevois, that's it The Pierre Fabre Immunology Center may well be one of the jewels in the Geneva-border area, it cultivates no less a sense of Normal secret when Implementing scientific research since 1988 at St. Juhen-en-Genevois, the Pierre Fabre immunology center will start its extension.

French Minister of Economy Christine Lagarde visits today, (the day as BioData).

This morning, Christine Lagarde, Minister of Economy, industry and employment, laying the first stone of a new building will be built or an "antibody biotechnology unit" for a bioproduction of monoclonal antibodies therapeutic proteins in the field of the fight against cancer immunology center of Saint-Julien, which employs nearly 120 people had accelerating its development of the year 2000 by making its unique online research on anti-cancer monoclonal antibodies and creating twenty positions between 2004 and 2008. The new building of 3000 m, and lead to the creation of 20 to 30 jobs other hand, this investment of  15 million done in collaboration and developed with existing institutions on the site of Archamps, including Biopark with which exchanges are planned.

Thraee questions : What is the site of Archamps? why positioning in biotechnology? "It seems to us that biotechnologies are a promising niche for very simple reason. We are looking for new activity sectors in the border area, because there is a rapid de-industrialization, we must overcome the deficit renewal economic. French-Geneva Leman Region is a leading center for biotechnology in Europe, apparently the third after England and Germany with industrial know-how that can combine companies there with the micromechanics, that called bio mecanics, a favorable tax environment and the fact that there are research and cross-border cooperation. Cross-border in this regard is a force to add the fact of competences between the universities of Geneva, Grenoble and Lyon. It was more the idea of Biopark "Can you explain or us the Biopark plans? "The Biopark is under development, the book is matenel and teams are being formed with Joseph-Founer University of Grenoble. Yes, the project was delayed initially. We had put on laboratory decentralization, CNRS or Inserm model. And then there were reforms, in terms the economy of public money, which asks the CNRS and linserm, research organizations, to refocus, rather than disseminate. So we had to review the strategy and the route we chose was cooperation with a university that sought international exposure and is very strong in this area,

This is happening on Tuesday and Wednesday after a year's absence. "The withdrawal of our main spon- sors three months prior to the show had forced us to cancel the edition of 2009. This meeting is reborn and is as traditionally between the third or fourth week of January," Liliane Daugny, spokesman of Biodata. With the feature of being located either in Geneva or Archamps. It positions the congress website as a reference in the sector of biotech. Judging the list of investors present at this edition as the last few years, the symposium is, to say the least, not gone unnoticed, nor this year as in the last editions (supported by Merck and Serono and BioAlps). "The funds responsible for us remained faithful and return with great ambitions in a period difficult for the industry," says Liliane Daugny.

The 2010 edition will host over seventy specialized investors and nearly 250 "one to one" are programmed between these entrepreneurs and financial experts. And enrollment is almost similar to that of 2008, when the last edition. "This is proof of the interest of the manifestation" adds Hervé de Kergrohen Chairman of Biodata.

more...